Condition
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Recruiting1
Terminated1
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05075980Phase 2Active Not Recruiting
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
NCT06971848Not ApplicableNot Yet RecruitingPrimary
Evaluation of Skin Tests in Biotherapy Allergies
NCT06580054Phase 2RecruitingPrimary
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
NCT05110781Phase 2TerminatedPrimary
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
Showing all 4 trials